The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Association of bone scan index (BSI) with prognostic biomarkers and survival in men with metastatic castration-resistant prostate cancer (mCRPC) enrolled in a prospective randomized controlled trial of tasquinimod.
Andrew J. Armstrong
Consultant or Advisory Role - Amgen; Bayer; Dendreon; Ipsen; Sanofi
Honoraria - Dendreon; Janssen-Ortho; Pfizer; Sanofi
Research Funding - Active Biotech; Dendreon; Ipsen; Janssen-Ortho; Medivation; Sanofi
Reza Kaboteh
No relevant relationships to disclose
Michael Anthony Carducci
Consultant or Advisory Role - Active Biotech
Jan-Erik Damber
No relevant relationships to disclose
Walter Michael Stadler
No relevant relationships to disclose
Hansen Mats
Employment or Leadership Position - Active Biotech
Lars Edenbrandt
Employment or Leadership Position - Exiqon
Stock Ownership - EXINI Diagnostics
Goran Forsberg
Employment or Leadership Position - Active Biotech
Stock Ownership - Active Biotech
Orjan Nordle
Employment or Leadership Position - Active Biotech
Roberto Pili
Consultant or Advisory Role - Ipsen
Research Funding - Active Biotech
Michael J. Morris
No relevant relationships to disclose